Clinical significance of repeat sextant biopsies in prostate cancer patients

Urology

Volumn 49, Issue 3 SUPPL., 1997, Pages 113-118

  Stroumbakis, Nicholas ^a   Cookson, Michael S ^b   Reuter, Victor E ^c   Fair, William R ^c  

^a Greenwich Associates   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; CANCER STAGING; CONFERENCE PAPER; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

ANDROGEN ANTAGONISTS; BIOPSY, NEEDLE; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; SELECTION BIAS; SENSITIVITY AND SPECIFICITY;

EID: 0030970742     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00178-7     Document Type: Conference Paper

References (24)

1. Hodge KK, McNeal JE, Terris MK, and Stamey TA: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142: 71-74, 1989.
2. Andriole GL, Coplen DE, and Catalona WJ: The ability of systematic transrectal ultrasound (TRUS) guided biopsy (Bx) to detect prostate cancer (CaP) prior to TURP (abst). J Urol 143(2): 364A, 1990.
3. Hammerer P, Gonnerman D, Dieringer J, and Huland H: Directed versus random ultrasound guided core biopsies of the prostate (abst). J Urol 143(2): 364A, 1990.
4. Vallancien G, Prapotinch D, Veilon B, Brisset JM, and Andre-Bougaran J: Systematic prostatic biopsies in 100 men with no suspicion of cancer on digital rectal examination. J Urol 146: 1308, 1991.
5. Hammerer P and Huland H: Systematic biopsies in 651 patients referred for prostate evaluation. J Urol 151: 99-102, 1994.
6. Brawer MK, and Nagle RB: Transrectal ultrasound guided prostate needle biopsy following negative digitally guided biopsy (abst). J Urol 141(2): 278A, 1989.
7. Rifkin MD, Alexander AA, Pisarchick J, and Matteucci T: Palpable masses in the prostate: superior accuracy of US-guided biopsy compared with accuracy of digitally guided biopsy. Radiology 179: 41, 1991.
8. Stamey TA: Making the most out of six systematic sextant biopsies. Urology 45: 2-12, 1995.
9. Epstein JI, Walsh PC, Carmichael M, and Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271: 368-374, 1994.
10. Peller PA, Young DC, and Marmaduke DP, et al: Sextant prostate biopsies. Cancer 75: 530-538, 1995.
11. Terris MK, McNeal JE, and Stamey TA: Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol 148: 829-832, 1992.
12. Bostwick DG, Quain J, and Bergstralh E, et al: Prediction of capsular perforation and seminal vesicle disease invasion in prostate cancer. Urology 155: 1361-1367, 1996.
13. Ackerman DA, Barry JM, and Wicklund RA, et al: Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 150: 1845-1850, 1993.
14. Ravery V, Boccon-Gibod LA, and Billebaud T: Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 44: 371-376, 1994.
15. Labrie F, Dupont A, and Cusan L, et al: Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 16(6): 499-509, 1993.
16. Fair WR, Aprikian AG, and Cohen D, et al: Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clin Invest Med 16: 516-522, 1993.
17. Van Poppel H, Ridder DD, and Elgamal A, et al: Neoadjuvant hormonal therapy before radical prostatectomy reduces the number of surgical margins in T2 prostate cancer: interim results of a prospective randomized trial. J Urol 154: 429-434, 1995.
18. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, and Puras-Baez A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMo) prostate cancer. J Urol 154: 424-428, 1995.
19. Cookson MS, and Fair WR, et al: Pathological staging and biochemical recurrence after neoadjuvant androgen therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Br J Urol (in press).
20. Keetch DW, Catalona WJ, and Smith DS: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151: 1571-1574, 1994
21. Roehborn CG, Pickens JG, and Sanders JS: Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnosis and prostate specific-antigen levels. Urology 47: 347-352, 1996.
22. Ellis WJ and Brawer MK: Repeat needle prostate biopsy: who needs it? J Urol 153: 1496-1498, 1995.
23. Daneshgari F, Taylor GD, Miller GJ, and Crawford ED: Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. Urology 5(4): 609-612, 1995.
24. Haggman M, Nybacka O, Nordin B, and Busch C: Standardized in vitro mapping with multiple core biopsies of total prostatectomy specimens: localization and prediction of tumor volume and grade. Br J Urol 74: 617-625, 1994.